Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

5820 - Phase II Study of Cetuximab Rechallenge in Patients with RAS Wild-Type metastatic Colorectal Cancer: E-Rechallenge Trial


21 Oct 2018


Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology


Targeted Therapy;  Immunotherapy

Tumour Site

Colon and Rectal Cancer


Hiroshi Osawa


Annals of Oncology (2018) 29 (suppl_8): viii150-viii204. 10.1093/annonc/mdy281


H. Osawa1, E. Shinozaki2, M. Nakamura3, Y. Ohhara4, Y. Shindo5, M. Shiozawa6, H. Uetake7, H. Matsumoto8, N. Ureshino9, H. Satake10, T. Kobayashi11, T. Suto12, S. Kitano13, Y. Ohashi14, K. Uemura15, K. Yamaguchi16

Author affiliations

  • 1 Department Of Oncology And Hematology, Edogawa Hospital, 133-0052 - Tokyo/JP
  • 2 Gastrointestinal Oncology, Cancer Institute Hospital of JFCR, 135-8550 - Tokyo/JP
  • 3 Aizawa Comprehensive Cancer Center, Aizawa Hospital, 390-8510 - Matsumoto/JP
  • 4 Department Of Gastroenterology, Sapporo Medical Center, Sapporo/JP
  • 5 Gastroenterological Surgery, Nakadori General Hospital, 010-8577 - Akita/JP
  • 6 Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama/JP
  • 7 Specialized Surgeries, Tokyo Medical and Dental University, Tokyo/JP
  • 8 Department Of Surgery, Cancer And Infectious Diseases Center, Tokyo Metropolitan Komagome Hospital, Tokyo/JP
  • 9 Medical Oncology, Saga-Ken Medical Center Koseikan, Saga/JP
  • 10 Department Of Medical Oncology, Kobe City Medical Center General Hospital, 650-0047 - Kobe/JP
  • 11 Department Of Medical Oncology, Kyorin University Faculty of Medicine, Mitaka/JP
  • 12 Department Of Gastroenterological Surgery, Yamagata Prefectural Central Hospital, Yamagata/JP
  • 13 Graduate School Of Engineering, Osaka University, Osaka/JP
  • 14 Integrated Science And Engineering For Sustainable Society, Chuo University, Tokyo/JP
  • 15 Division Of Biostatistics And Bioinformatics, Interfacluty Initiative In Information Studies, The University of Tokyo, Tokyo/JP
  • 16 Department Of Gastroenterology, Cancer Institute Hospital of JFCR, 135-8550 - Tokyo/JP


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 5820


Several previous reports indicated that cetuximab (Cmab) rechallenge may be efficacious in patients for whom Cmab was previously effective. On the other hand, some reports did not support this. Considering the plasticity of sensitive clone, we assumed that an anti-EGFR antibody-free interval (aEFI) and efficacy may be correlated. This current study investigates the efficacy and safety of Cmab rechallenge as a salvage chemotherapy.


The E-Rechallenge tiral is a multicenter phase II study in mCRC patients who have become refractory to fluoropyrimidines, L-OHP, CPT-11, Cmab and bevacizumab, and in whom previous treatment with Cmab was effective in any earlier line (achieving CR, PR, or SD that persisted for ≥6 months). The other main eligibility criteria are; RAS wild-type, measurable disease, aEFI ≥16 weeks between the last dose of Cmab during previous treatment and the start of Cmab rechallenge. Protocol treatment is the combination of weekly Cmab with biweekly CPT-11. The primary endpoint is response rate (RR). Secondary endpoints are progression free survival (PFS), overall survival (OS), association between the aEFI and efficacy, and safety. Using a single-stage binominal design, 45 patients were required; a RR of ≥ 20% was considered promising, and a RR of ≤ 5% unacceptable (one-sided α = 2.5%, β = 10%). Additional research of ctDNA was conducted optionally.


Between Dec 2014 and Oct 2017, 33 patients were enrolled. Patients’ characteristics were as follows; mean age 64.4, male/female 84.8%/15.2%, primary location right/left 12.1%/87.9% and the efficacy in previous Cmab, CR/PR/SD ≥6 months 3%/78.8%/18.2%, respectively. The primary endpoint; the rates of PR/SD/PD (95%CI) were PR 15.6% (5.3-32.7%)/SD 40.6% (23.6-57.6%)/ PD 43.8% (26.4-62.3%). Secondary endpoint; median PFS and OS (95%CI) were 88 days (62-113days) and 262 days (195-307days). There were no statistical significant difference of PFS stratified by median aEFI. New signals of adverse events were not identified.


Cmab rechallenge showed some activity in the salvage setting, in patients for whom Cmab was previously effective. The additional research of ctDNA may contribute to identify patients with benefit from Cmab rechallenge.

Clinical trial identification

UMIN 000016439.

Legal entity responsible for the study

Comprehensive Support Project for Oncological Research.


Merck Serono.

Editorial Acknowledgement


E. Shinozaki, H. Satake: Honoraria: Merck Serono. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.